Roth Capital Starts Biofrontera (BFRI) at Buy

November 24, 2021 7:19 AM EST Send to a Friend
Roth Capital analyst Jonathan Aschoff initiates coverage on Biofrontera (NASDAQ: BFRI) with a Buy rating and a price target of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login